Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Cyclopentanohydrophenanthrene ring system doai
Reexamination Certificate
1999-05-28
2004-08-24
Badio, Barbara P. (Department: 1616)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Cyclopentanohydrophenanthrene ring system doai
C540S111000
Reexamination Certificate
active
06780853
ABSTRACT:
BACKGROUND OF THE INVENTION
1. Field of the Invention
The present invention is directed to novel steroid derivatives of the androstane and pregnane series, as well as pharmaceutical compositions and methods for modulating brain excitability. More particularly, the invention relates to 3&agr;-hydroxy, 17-(un)substituted derivatives of the androstane series and 21-substituted derivatives of the pregnane series.
2. Related Art
Brain excitability is defined as the level of arousal of an animal, a continuum that ranges from coma to convulsions, and is regulated by various neurotransmitters. In general, neurotransmitters are responsible for regulating the conductance of ions across neuronal membranes. At rest, the neuronal membrane possesses a potential (or membrane voltage) of approximately −80 mV, the cell interior being negative with respect to the cell exterior. The potential (voltage) is the result of ion (K
+
, Na
−
, Cl
−
, organic anions) balance across the neuronal semipermeable membrane. Neurotransmitters are stored in presynaptic vesicles and are released under the influence of neuronal action potentials. When released into the synaptic cleft, an excitatory chemical transmitter such as acetylcholine will cause membrane depolarization (change of potential from −80 mV to −50 mV). This effect is mediated by postsynaptic nicotinic receptors which are stimulated by acetylcholine to increase membrane permeability to Na
+
ions. The reduced membrane potential stimulates neuronal excitability in the form of a postsynaptic action potential.
In the case of the GABA receptor complex (GRC), the effect on brain excitability is mediated by GABA, a neurotransmitter. GABA has a profound influence on overall brain excitability because up to 40% of the neurons in the brain utilize GABA as a neurotransmitter. GABA regulates the excitability of individual neurons by regulating the conductance of chloride ions across the neuronal membrane. GABA interacts with its recognition site on the GRC to facilitate the flow of chloride ions down an electrochemical gradient of the GRC into the cell. An intracellular increase in the levels of this anion causes hyperpolarization of the transmembrane potential, rendering the neuron less susceptible to excitatory inputs (i.e., reduced neuron excitability). In other words, the higher the chloride ion concentration in the neuron, the lower the brain excitability (the level of arousal).
It is well-documented that the GRC is responsible for the mediation of anxiety, seizure activity, and sedation. Thus, GABA and drugs that act like GABA or facilitate the effects of GABA (e.g., the therapeutically useful barbiturates and benzodiazepines (BZs), such as Valium) produce their therapeutically useful effects by interacting with specific regulatory sites on the GRC.
Accumulated evidence has now indicated that in addition to the benzodiazepine and barbiturate binding site, the GRC contains a distinct site for neuroactive steroids (Lan, N. C. et at,
Neurochem. Res
. 16:347-356 (1991)). Neuroactive steroids can occur endogenously. The most potent endogenous neuroactive steroids are 3&agr;-hydroxy-5-reduced pregnan-20-one and 3&agr;,21-dihydroxy-5-reduced pregnan-20-one, metabolites of hormonal steroids progesterone and deoxycorticosterone, respectively. The ability of these steroid metabolites to alter brain excitability was recognized in 1986 (Majewska, M. D. et al.,
Science
232:1004-1007 (1986); Harrison, N. L. et al.,
J. Pharmacol. Exp. Ther
. 241:346-353 (1987)). However, the therapeutic usefulness of these steroid metabolites and their derivatives (neuroactive steroids) was not recognized by workers in the field due to an incomplete understanding of the potency and site of action of these neuroactive steroids. Applicants' invention relates in part to a pharmaceutical application of the knowledge gained from a more developed understanding of the potency and site of action of certain steroid compounds.
The ovarian hormone progesterone and its metabolites have been demonstrated to have profound effects on brain excitability (Backstrom, T. et al.,
Acta Obstet. Gynecol. Scand. Suppl
. 130:19-24 (1985); Pfaff, D. W. and McEwen, B. S.,
Science
219:808-814 (1983); Gyermek et al.,
J. Med. Chem
. 11:117 (1968); Lambert, J. et al.,
Trends Pharmacol. Sci
. 8:224-227 (1987)). The levels of progesterone and its metabolites vary with the phases of the menstrual cycle. It has been well documented that progesterone and its metabolites decrease prior to the onset of menses. The monthly recurrence of certain physical symptoms prior to the onset of menses has also been well documented. These symptoms, which have become associated with premenstrual syndrome (PMS) include stress, anxiety, and migraine headaches (Dalton, K.,
Premenstrual Syndrome and Progesterone Therapy
, 2nd edition, Chicago Yearbook, Chicago (1984)). Patients with PMS have a monthly recurrence of symptoms that are present in premenses and absent in postmenses.
In a similar fashion, a reduction in progesterone has also been temporally correlated with an increase in seizure frequency in female epileptics, i.e., catamenial epilepsy (Ladlaw, J.,
Lancet
, 1235-1237 (1956)). A more direct correlation has been observed with a reduction in progesterone metabolites (Rosciszewska et al.,
J. Neurol. Neurosurg. Psych
. 49:47-51 (1986)). In addition, for patients with primary generalized petit mal epilepsy, the temporal incidence of seizures has been correlated with the incidence of the symptoms of premenstrual syndrome (Backstrom, T. et al.,
J. Psychosom. Obstet. Gynaecol
. 2:8-20 (1983)). The steroid deoxycorticosterone has been found to be effective in treating patients with epileptic spells correlated with their menstrual cycles (Aird, R. B. and Gordan, G.,
J. Amer. Med. Soc
. 145:715-719 (1951)).
A syndrome also related to low progesterone levels is postnatal depression (PND). Immediately after birth, progesterone levels decrease dramatically leading to the onset of PND. The symptoms of PND range from mild depression to psychosis requiring hospitalization. PND is also associated with severe anxiety and irritability. PND-associated depression is not amenable to treatment by classic antidepressants and women experiencing PND show an increased incidence of PMS (Dalton, K.,
Premenstrual Syndrome and Progesterone Therapy
, 2nd edition, Chicago Yearbook, Chicago (1984)).
Collectively, these observations imply a crucial role for progesterone and deoxycorticosterone and more specifically their metabolites in the homeostatic regulation of brain excitability, which is manifested as an increase in seizure activity or symptoms associated with catamenial epilepsy, PMS and PND. The correlation between reduced levels of progesterone and the symptoms associated with PMS, PND, and catamenial epilepsy (Backstrom, T. et al.,
J. Psychosom. Obstet. Gynaecol
. 2:8-20 (1983)); Dalton, K.,
Premenstrual Syndrome and Progesterone Therapy
, 2nd edition, Chicago Yearbook, Chicago (1984)) has prompted the use of progesterone in their treatment (Mattson et al., “Medroxyprogesterone therapy of catamenial epilepsy,” in
Advances in epileptology: XVth Epilepsy International Symposium
, Raven Press, New York (1984), pp. 279-282, and Dalton, K.,
Premenstrual Syndrome and Progesterone Therapy
, 2nd edition, Chicago Yearbook, Chicago (1984)). However, progesterone is not consistently effective in the treatment of the aforementioned syndromes. For example, no dose-response relationship exists for progesterone in the treatment of PMS (Maddocks, et al.,
Obstet. Gynecol
. 154:573-581 (1986); Dennerstein, et al.,
Brit. Med. J
. 290:16-17 (1986)).
Templeton et al.,
Steroids
48:339-346 (1986) discloses a stereoselective and regioselective reduction of steroid ketones to form axial alcohols at C-3. The compound 17&bgr;-methoxy-2&bgr;-methyl-5&agr;-androstan-3&agr;-ol is formed from 17&bgr;-methoxy-2&agr;,3&agr;-epoxy-5&agr;-androstane.
Grieco et al.,
J. Am. Chem. Soc
. 11:7799-7801 (1990) discloses the u
Fick David B.
Hogenkamp Derk J.
Lan Nancy C.
Upasani Ravindra B.
Badio Barbara P.
Euro-Celtique S.A.
Sterne Kessler Goldstein & Fox P.L.L.C.
LandOfFree
Neuroactive steroids of the androstane and pregnane series does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Neuroactive steroids of the androstane and pregnane series, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Neuroactive steroids of the androstane and pregnane series will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3358300